Article
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
The oncologist - 1 Feb 2021
Sena Laura A, Fountain Julia, Isaacsson Velho Pedro, Lim Su Jin, Wang Hao, Nizialek Emily, Rathi Nityam, Nussenzveig Roberto, Maughan Benjamin L, Velez Miguel Gonzalez, Ashkar Ryan, Larson Amanda C, Pritchard Colin C, Adra Nabil, Bryce Alan H, Agarwal Neeraj, Pardoll Drew M, Eshleman James R, Lotan Tamara L, Antonarakis Emmanuel S
Abstract excerpt
BACKGROUND: Genomic biomarkers that predict response to anti-PD1 therapy in prostate cancer are needed. Frameshift mutations are predicted to generate more neoantigens than missense mutations; therefore, we hypothesized that the number or proportion of tumor frameshift mutations would correlate with response to anti-PD1 therapy in prostate cancer. METHODS: To enrich for response to anti-PD1 therapy, we assembled...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.